Literature DB >> 22407982

Equilibrium and kinetic analysis of human interleukin-13 and IL-13 receptor alpha-2 complex formation.

Eilyn R Lacy1.   

Abstract

Interleukin 13 (IL-13) is a pleiotropic cytokine secreted by activated T cells. Both IL-13 and its polymorphic variant (IL-13-R110Q) have been shown to be associated with multiple diseases such as asthma and allergy. Two IL-13 receptors have been identified, IL-13R alpha-1 receptor (IL-13Rα1) and IL-13R alpha-2 receptor (IL-13Rα2). It has been well established that IL-13 binds to IL-13Rα1 alone with low nM affinity while binding to the IL-13Rα1/IL-4R receptor complex is significantly tighter (pM). The affinity between IL-13 and IL-13Rα2, however, remains elusive. Several values have been reported in the literature varying from 20 pM to 2.5 nM. The affinities previously reported were obtained using surface plasmon resonance (SPR) or Scatchard analysis of (125) I-IL-13 binding data. This report presents the results for the kinetics and equilibrium binding analysis studies performed using label-free kinetic exclusion assay (KEA) for the interaction of human IL-13 and IL-13Rα2. KEA equilibrium analysis showed that the affinities of IL-13Rα2 are 107 and 56 pM for IL-13 and its variant (IL-13-R110Q), respectively. KEA kinetic analysis showed that a tight and very stable complex is formed between IL-13Rα2 and IL-13, as shown by calculated dissociation rate constants slower than 5 × 10(-5) per second. Kinetic analysis also showed significant differences in the kinetic behavior of wild type (wt) versus IL-13-R110Q. IL-13-R110Q not only associates to IL-13Rα2 slower than wt human IL-13 (wt-IL-13), as previously reported, but IL-13-R110Q also dissociates slower than wt-IL-13. These results show that IL-13Rα2 is a high affinity receptor and provide a new perspective on kinetic behavior that could have significant implications in the understanding of the role of IL-13-R110Q in the disease state.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407982     DOI: 10.1002/jmr.2150

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  3 in total

Review 1.  Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis.

Authors:  Xiao-Lei Huang; Yu-Jie Wang; Jun-Wei Yan; Ya-Nan Wan; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflamm Res       Date:  2015-03-01       Impact factor: 4.575

2.  RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.

Authors:  Catherine S Tripp; Carolyn Cuff; Andrew L Campbell; Barbara A Hendrickson; Jeff Voss; Terry Melim; Chengbin Wu; Andrew D Cherniack; Kenneth Kim
Journal:  Adv Ther       Date:  2017-04-28       Impact factor: 3.845

3.  Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease.

Authors:  Erik P Karmele; Trisha S Pasricha; Thirumalai R Ramalingam; Robert W Thompson; Richard L Gieseck; Kayla J Knilans; Martin Hegen; Mark Farmer; Fang Jin; Aaron Kleinman; David A Hinds; Thiago Almeida Pereira; Rafael de Queiroz Prado; Nan Bing; Lioudmila Tchistiakova; Marion T Kasaian; Thomas A Wynn; Kevin M Vannella
Journal:  Mucosal Immunol       Date:  2019-07-15       Impact factor: 7.313

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.